The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study

被引:16
|
作者
Gerhardsen, Gerhard [1 ]
Hansen, Anne V. [2 ]
Killi, Marianne [3 ]
Fornitz, Gitte Gleerup [4 ]
Pedersen, Frank [5 ]
Roos, Signe Barfod [6 ,7 ]
机构
[1] Greverud Legesenter, Oppegard 1415, Norway
[2] Univ Copenhagen, Fac Life Sci, Copenhagen, Denmark
[3] Fartein Valens Vej 45, Kolbotn, Norway
[4] Amager Hosp, Med Ctr, Copenhagen, Denmark
[5] Herning Hosp, Herning, Denmark
[6] Kommune Hosp Copenhagen, Dept Clin Biochem, Gentofte, Denmark
[7] Univ Copenhagen, Hellerup, Denmark
关键词
herbal medicinal product; pollen; premenstrual syndrome; sleep disturbance;
D O I
10.1007/s12325-008-0072-4
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction: A double-blind, placebo-controlled, randomised, parallel-group, multicentre study was conducted to evaluate the effect of a pollen-based herbal medicinal product, Femal (R) (Sea-Band Ltd, Leicestershire, UK), on premenstrual sleep disturbances (PSD) in women with premenstrual syndrome (PMS). Methods: Femal, 160 mg twice-daily, was given for four menstrual cycles to 50 women, and placebo to 51 women. PSD were evaluated on a visual analogue scale prior to and after the four cycles. The effect on overall PMS symptoms was assessed with the Steiner premenstrual tension syndrome (PMTS) self-rating questionnaire. The results were analysed statistically based on intention to treat. Results: Femal treatment resulted in a significant reduction in PSD (P < 0.05) whereas placebo had no significant effect (P > 0.05). In a subgroup analysis of women with irritability as their main PMS symptom cluster, the reduction of PSD was even more pronounced (P < 0.001). There was no significant difference in overall degree of PMS symptom reduction between Femal and placebo when all participating women were evaluated (P > 0.05). However, in women with irritability as their main PMS symptom cluster, Femal treatment resulted in a significant reduction of the Steiner score (P < 0.05). The frequency of adverse events was not significantly different in women on Femal compared to women on placebo (P > 0.05). No serious adverse events were recorded. Conclusions: Femal treatment reduced PSD to a significant degree, particularly in women with irritability as their main PMS symptom. Femal treatment also reduced overall PMS symptoms in women with irritability (but not dysphoria) as their main PMS symptom. The safety of Femal and its efficacy in PSD and other symptoms in women with irritability as the main symptom cluster makes this herbal medicinal product a promising addition to the therapeutic arsenal for women with PMS.
引用
收藏
页码:595 / 607
页数:13
相关论文
共 50 条
  • [1] The efficacy of Femal in women with premenstrual syndrome: a randomised, double-blind, parallel-group, placebo-controlled, multicentre study
    Gerhard Gerhardsen
    Anne V. Hansen
    Marianne Killi
    Gitte Gleerup Fornitz
    Frank Pedersen
    Signe Barfod Roos
    Advances in Therapy, 2008, 25
  • [2] A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
    Schmidt, Wolfgang A.
    Dasgupta, Bhaskar
    Luqmani, Raashid
    Unizony, Sebastian H.
    Blockmans, Daniel
    Lai, Zhihong
    Kurrasch, Regina H.
    Lazic, Ivana
    Brown, Kurt
    Rao, Ravi
    RHEUMATOLOGY AND THERAPY, 2020, 7 (04) : 793 - 810
  • [3] A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Giant Cell Arteritis
    Wolfgang A. Schmidt
    Bhaskar Dasgupta
    Raashid Luqmani
    Sebastian H. Unizony
    Daniel Blockmans
    Zhihong Lai
    Regina H. Kurrasch
    Ivana Lazic
    Kurt Brown
    Ravi Rao
    Rheumatology and Therapy, 2020, 7 : 793 - 810
  • [4] Assessment of the effects of the herbal remedy Femal on the symptoms of premenstrual syndrome: A randomized, double-blind, placebo-controlled study
    Winther, K
    Hedman, C
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2002, 63 (05): : 344 - 353
  • [5] The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial
    Sha, Zhongwei
    Hou, Yiping
    Xue, Chunchun
    Li, Ou
    Li, Zhimin
    Wang, Huiru
    Zhang, Wenjing
    Xu, Jian
    TRIALS, 2020, 21 (01)
  • [6] The efficacy and safety of 'antianxiety granule' for anxiety disorder: a multicentre, randomized, double-blind, placebo-controlled, parallel-group trial
    Zhongwei Sha
    Yiping Hou
    Chunchun Xue
    Ou Li
    Zhimin Li
    Huiru Wang
    Wenjing Zhang
    Jian Xu
    Trials, 21
  • [7] Efficacy of resveratrol in the treatment of unipolar depression: double-blind randomized placebo-controlled parallel-group study
    Aftanas, L. I.
    Markov, A. A.
    Rikita, M. V.
    Danilenko, K. V.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S189 - S189
  • [8] Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study
    Keary, Christopher
    Bird, Lynne M.
    de Wit, Marie-Claire
    Hatti, Shivkumar
    Heimer, Gali
    Heussler, Helen
    Kolevzon, Alexander
    Mathews, Adera
    Ochoa-Lubinoff, Cesar
    Tan, Wen-Hann
    Yan, Ying
    Adams, Maxwell
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2023, 47 : 6 - 12
  • [9] SECUKINUMAB IN GIANT CELL ARTERITIS: THE RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE PHASE 2 TITAIN TRIAL
    Venhoff, N.
    Schmidt, W. A.
    Bergner, R.
    Rech, J.
    Unger, L.
    Tony, H. P.
    Mendelson, M.
    Sieder, C.
    Maricos, M.
    Thiel, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 121 - 122
  • [10] Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA)
    Reetz, Kathrin
    Hilgers, Ralf-Dieter
    Isfort, Susanne
    Dohmen, Marc
    Didszun, Claire
    Fedosov, Kathrin
    Kistermann, Jennifer
    Mariotti, Caterina
    Durr, Alexandra
    Boesch, Sylvia A.
    Klopstock, Thomas
    Garrido, Francisco Javier Rodriguez de Rivera
    Schoels, Ludger
    Klockgether, Thomas
    Pandolfo, Massimo
    Korinthenberg, Rudolf
    Lavin, Philip
    Molenberghs, Geert
    Libri, Vincenzo
    Giunti, Paola
    Festenstein, Richard
    Schulz, Joerg B.
    NEUROLOGICAL RESEARCH AND PRACTICE, 2019, 1 (01):